Clinical Trials Logo

COVID-19 clinical trials

View clinical trials related to COVID-19.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT04841759 Recruiting - COVID-19 Clinical Trials

The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The SARS-CoV2 pandemic has kept the world in suspense for over a year now. Almost 100 million people around the world have contracted COVID-19 to date and over 2 million people have died of COVID-19 by the end of January 2021. Despite the tragedy of these deaths, it must be pointed out at this point that the number of COVID-19 survivors is significantly larger. These COVID-19 survivors are now the focus of interest in rehabilitation measures, as it has been shown that survival of the disease does not go hand in hand with a complete cure. Thirty-five percent of all COVID-19 survivors and 87% of the COVID-19 survivors who were hospitalized in the course of their illness suffer from after-effects that are currently summarized as post-COVID fatigue syndrome also known as "Long-COVID". As health care workers are at higher risk of contracting SARS CoV2 and furthermore, considering their central role in the overcoming of this pandemic, a COVID-19 rehabilitation program for healthcare workers of the Medical University of Vienna, Austria as well as the General Hospital of Vienna, Austria - together the second-largest university-clinic in the world - was developed as part of workplace health promotion. Nowadays, the fatigue syndrome is primarily known as a side effect of cancer treatment and thus from the rehabilitation of cancer patients. Cancer-related fatigue is a massive limiting side effect for patients and the currently most effective treatment strategy against cancer-associated fatigue syndrome is physical training. The idea for this current project is, that physical exercise might have similar effects on post-SARS-CoV2 fatigue as it has on cancer-related fatigue. The current study evaluates the effects of this primarily exercise-based rehabilitation program on Long-COVID fatigue.

NCT ID: NCT04839965 Recruiting - COVID-19 Clinical Trials

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

Start date: April 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2 randomized study to evaluate the safety and efficacy of IV Ampion in improving the clinical course and outcomes of adult COVID-19 patients requiring supplemental oxygen.

NCT ID: NCT04836052 Recruiting - COVID-19 Clinical Trials

Omega-3 Oil Use in COVID-19 Patients in Qatar

Omega3
Start date: December 24, 2020
Phase: Phase 3
Study type: Interventional

COVID-19 infection has been widely spread since December 2019 and causing many comorbidities and fatalities. The most common clinical presentation of COVID-19 patients admitted to ICUs is respiratory failure , hypoxia and acute lung injury. While new therapies and vaccines are urgently being investigated, they may take an inordinate time to get to right people. Omega-3-oil has been shown to have less proinflammatory mediators that may have immunomodulating, anti-inflammatory and antiviral effect. Two main fatty acids in omega-3-oil including eicosapentaenoic acid and docosahexaenoic acid have shown benefit in patients with ARDS as well. So, the investigators proposed a randomized controlled study to evaluate the effectiveness of omega-3-oil supplementation 2 gm PO/NGT/OGT twice daily for 28 days or till discharge or till death in COVID-19 critically ill patients admitted to ICU who require oxygen support.

NCT ID: NCT04833101 Recruiting - COVID-19 Clinical Trials

Study on Sequential Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

Start date: April 7, 2021
Phase: Phase 4
Study type: Interventional

This is a randomized, observer-blind, placebo-controlled study, for evaluation of safety and immunogenicity of sequential immunization of recombinant COVID-19 vaccine (adenovirus type-5 vector) and RBD-based protein subunit vaccine (ZF2001) against COVID-19 in Chinese healthy population. 120 healthy subjects aged over 18 years of age who have been vaccinated with recombinant adenovirus type-5 vectored vaccine will be recruited in this study. Of them, 60 subjects will be enrolled in the "0-28 days" regimen and other 60 will be enrolled in "0-56 days" regimen. Subjects in each regimen will be randomly vaccinated with the boost dose of subunit vaccine(ZF2001) against COVID-19 or a commercial influenza vaccine in a ratio of 2:1. The occurrence of adverse events within 28 days and serious adverse events within 6 months after vaccination will be observed. In addition, blood samples will be collected on the day 0 before and after the boost vaccination on day 14, 28 and 6 months after second vaccination to test serum antibody levels and to profile the immune cells' subgroups and germlines. Each subject will remain in this study for approximately 6 months.

NCT ID: NCT04832022 Recruiting - COVID-19 Clinical Trials

Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination

COVID-RIC3
Start date: April 7, 2021
Phase:
Study type: Observational

To date, studies on SARS-CoV2and vaccines have been mostly from the general population not exposed to immunosuppressants. The efficacy and safety of COVID-19 vaccines need to be evaluated in these populations.

NCT ID: NCT04828668 Recruiting - Covid 19 Clinical Trials

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.

"BAC-PAC"
Start date: April 2, 2021
Phase: N/A
Study type: Interventional

This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".

NCT ID: NCT04824391 Recruiting - COVID-19 Clinical Trials

Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19

Start date: February 10, 2021
Phase: Phase 2
Study type: Interventional

The objective is to determine the efficacy, immunogenicity and safety of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the efficacy and safety in prophylaxis of COVID-19.

NCT ID: NCT04820803 Recruiting - COVID-19 Clinical Trials

Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19

Start date: February 3, 2021
Phase: N/A
Study type: Interventional

Pilot, randomized and controlled clinical trial for the evaluation of the decrease in the viral load of SARS-CoV-2 in the oropharynx in patients with COVID-19 through the use of mouthwash containing cetylpyridinium chloride (CPC) (0.07%) in mouthwash.

NCT ID: NCT04819802 Recruiting - Covid-19 Clinical Trials

MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients

MICROVID
Start date: March 28, 2021
Phase:
Study type: Observational

Microcirculatory dysfunction appears to play a key role in the development of organ failure leading to the death of patients with coronavirus disease 2019 (Covid-19). It is still uncertain today whether this damage is secondary to direct viral infection of endothelial cells or the consequence of the inappropriate inflammatory response induced by the infection. The analysis of endothelial and microcirculatory dysfunctions and glycocalyx degradation therefore appears to be necessary in the understanding of the pathophysiological mechanisms of Covid sepsis and could play a role in the evaluation of the efficacy of certain therapeutics which would aim at improving regional perfusion by decreasing microcirculatory dysfunction.However, the analysis of microcirculatory failure, endothelial dysfunction and glycocalyx degradation has so far only been evaluated in small cohorts, without quantitative analysis of microcirculatory perfusion

NCT ID: NCT04816669 Recruiting - COVID-19 Clinical Trials

Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of BNT162b2 Against COVID-19 in Healthy Adults

Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

This Phase 3 study will evaluate the safety and tolerability of lyophilized BNT162b2 presented in single-dose vials and of frozen liquid BNT162b2 in multidose vials and demonstrate that the immune response of the lyophilized formulation is noninferior: - As a 2-dose schedule (separated by 21 days) - At a dose of 30µg (as studied in the Phase 2/3 study C4591001) - In healthy adults 18 through 55 years of age - The duration of the study for each participant will be approximately 2 months (3 visits in total) - The study will be conducted in the United States